补益强心片治疗慢性心力衰竭临床研究

目的：探讨补益强心片治疗慢性心力衰竭（ CHF）的临床疗效。方法：将86例CHF患者随机分为对照组和观察组，每组各43例。对照组予以盐酸贝那普利片、倍他乐克片、地高辛片、氢氯噻嗪片口服，配合非药物干预治疗。观察组在对照组基础上加用补益强心片，两组疗程均为8周。观察治疗前后Lee氏心力衰竭计分、心室射血分数（ LVEF）、心输出量（ CO）、心房利钠多肽（ ANP）、N末端B型钠尿肽（ NT-proBNP）、血管紧张素Ⅱ（ AngⅡ）及醛固酮（ ALD）水平。结果：观察组Lee氏心力衰竭疗效有效率90.70%，优于对照组的74.42%（P〈0.05）；治疗后两组Lee氏心力衰竭评分较治疗前下降，观察组低于对照组（P〈0.01）；治疗后两组LVEF和CO均上升，观察组高于对照组，差异有统计学意义（P〈0.01）；治疗后观察组血浆ANP、NT-proBNP、AngⅡ及ALD水平低于对照组（ P〈0.01）。结论：在西医常规治疗的基础上，补益强心片能进一步改善CHF患者心功能，其作用机制可能与其下调RAAS系统及对ANP、NT-proBNP等细胞因子的调节有关。

Relatively Strong Heart Piece of Clinical Studies in Patients with Chronic Heart Failure

Objective：To investigate the relatively strong heart piece the clinical curative effect of treatment of chronic heart failure （ CHF）. Methods：86 patients with CHF were randomly divided into control group and observation group,43 cases in each group. Control group to hydrochloric acid that captopril and betaloc pills,digoxin,hydrochlorothiazide tablets,cooperate with the drug intervention ther-apy. Based on observation group in the control group with relatively strong heart,two groups of a course of 8 weeks. Score were observed before and after treatment of Lee＆#39;s heart failure and ventricular ejection fraction（ LVEF）and cardiac output（ CO）,atrial natriuretic polypeptide（ANP）,N end of b-type natriuretic peptide（NT-proBNP）,angiotensin Ⅱ（Ang Ⅱ）and aldosterone（ALD）level. Re-sults：the curative effect of observation group of Lee＆#39;s heart failure effective rate was 90. 7%,74. 42% better than that of control group （P〈0. 05）;Two groups of Lee＆#39;s heart failure score after treatment was decreased,the observation group is lower than the control group （P〈0. 01）;LVEF and CO in the two groups were increased after the treatment,the observation group is higher than the control group, the difference was statistically significant（P〈0. 01）;Plasma ANP group after treatment,the NT-proBNP,AngⅡand ALD levels lower than the control group（P〈0. 01）. Conclusion：on the basis of conventional western medicine treatment,relatively strong heart can fur-ther improve cardiac function in patients with CHF,its mechanism of action and possible downgrade RAAS system,the ANP and the NT-proBNP regulation of cytokines.